A potential predictive marker for response to interferon in malignant melanoma;Methylthioadenosin-phosphorylase (MTAP): Potentieller marker für ein ansprechen auf interferon-therapie beim malignen melanom

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 6, 2007, Pages 456-459

  Wild, Peter J ^a   Meyer, Stefanie ^b   Landthaler, Michael ^b   Hofstaedter, Ferdinand ^c   Bosserhoff, Anja Katrin ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Biomarker; Interferon; Malignant melanoma; Therapy

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; BIOLOGICAL MARKER; INTERFERON;

CANCER INVASION; CHROMOSOME 9P; GENE LOCATION; HUMAN; MELANOMA; METASTASIS; METHYLATION; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTERFERONS; MELANOMA; NEOPLASM PROTEINS; PURINE-NUCLEOSIDE PHOSPHORYLASE; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34250306444     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06303.x     Document Type: Review

References (15)

1. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002; 62: 6639-6644.
2. Garcia-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002; 8: 782-787.
3. Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T. The methylthioadenosine phosphorylase gene is frequently codeleted with the p16INK4a gene in acute type adult T-cell leukemia. Int J Cancer 1998; 75: 51-56.
4. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997; 57: 2619-2622.
5. Kamatani N and Carson DA. Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. Cancer Res 1980; 40: 4178-4182.
6. Della RF, Russo G, Oliva A, Mastropietro S, Mancini A, Borrelli A, Casero RA, Iolascon A, Zappia V. 5′-Deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene 1995; 10: 827-833.
7. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003; 163: 683-690.
8. Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, Vogt T, Landthaler M, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors. Arch Dermatol 2006; 142: 471-476.
9. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, David M. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001; 104: 731-741.
10. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
11. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458.
12. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
13. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, Macleod AR, Borden EC. Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation. J Clin Oncol 2006; 24: 3771-3779.
14. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662.
15. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94: 1-5.